Hazards, risks, and threats of heart disease from the early stages to symptomatic coronary heart disease and cardiac failure

Cardiovascular Drugs and Therapy

Volumn 11, Issue SUPPL. 1, 1997, Pages 199-212

  Kannel, William B ^a  

^a BOSTON UNIVERSITY   (United States)

Author keywords

Coronary heart disease; Heart failure; Risk factors

Indexed keywords

CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPOPROTEIN A;

AGE; ANGINA PECTORIS; ARTICLE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CIGARETTE SMOKING; CONGESTIVE HEART FAILURE; CORONARY ARTERY ATHEROSCLEROSIS; DIABETES MELLITUS; DISEASE COURSE; DYSLIPIDEMIA; FEMALE; GLUCOSE INTOLERANCE; HAZARD; HEART DISEASE; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE HYPERTROPHY; HEART MURMUR; HEART MUSCLE REVASCULARIZATION; HEART RATE; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; MALE; MENOPAUSE; MORTALITY; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; RISK; SEX DIFFERENCE; SUDDEN DEATH; SURVIVAL; SYSTOLIC BLOOD PRESSURE; VITAL CAPACITY;

AGE FACTORS; ARTERIOSCLEROSIS; CARDIOVASCULAR DISEASES; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; RISK FACTORS; SEX FACTORS;

EID: 0030993626     PISSN: 09203206     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1007792820944     Document Type: Article

References (46)

1. Kannel WB. Clinical misconceptions dispelled by epidemiologic research. Circulation 1995;92:3350-3360.
2. Kannel WB, McGee DL. Modifiable risk factors for sudden coronary death. In: Morganroth J, Horowitz LN, eds. Sudden Cardiac Death. New York: Grune & Stratton, 1985;267-284.
3. Gordon T, Kannel WB, Hjortland MC, McNamara P. Menopause and coronary heart disease. Ann Intern Med 1978;89:157-161.
4. Kannel WB, Hjortland MC, McNamara PM, Gordon T. Menopause and risk of cardiovascular disease. The Framingham Study. Ann Intern Med 1976;85:447-452.
5. Kannel WB, Abbott RD. Incidence and prognosis of unrecognized myocardial infarction. N En J Med 1984;311:1144-1147.
6. Kannel WB, Dannenberg AL, Abbott RD. Unrecognized myocardial infarction and hypertension. The Framingham Study. Am Heart J 1985;109:581-585.
7. Murabito JM, Evans JC, Larson MG, Levy D. Prognosis after the onset of coronary heart disease. An investigation of differences in outcome between the sexes according to initial coronary disease presentation. Circulation 1993;88:2548-2555.
8. Kannel WB. Risk factors for atheroslcerotic cardiovascular outcomes in different arterial territories. J Cardiovasc Risk 1994;1:333-339.
9. Anderson KM, Wilson PWF, Odell MP, Kannel WB. An updated coronary risk profile. A statement for health professionals. AHA statement. Circulation 1991;83:356-362.
10. Kannel WB. Multivariate cardiovascular risk assessment. J Myocar Ischem 1993;5:30-34.
11. Roussou W. Review of international trials. In: Program and Abstracts of the NHLBI Conference on Cholesterol and Heart Disease in Older Persons and Women, June 18-19, 1990, Bethesda, MD.
12. Ornish D, Brown SE, Sherovitz LW, et al. Can lifestyle changes reverse coronary heart disease? Lancet 1990;336:129-133.
13. Kane JP, Malloy MJ, Porta JA, Phillips NR, Diehl JC, Havel RJ. Regression of coronary atherosclerosis during treatment of familial hypercholesterolemia with combined drug regimens. JAMA 1991;264:3007-3012.
14. Brenskie JF, Levy RI, Kelsey SF, et al. Effects of therapy with cholestyramine on progression of coronary atherosclerosis: Results of NHLBI Type II coronary prevention study. Circulation 1984;69:313-324.
15. Levine GN, Keaney JF Jr, Vita JA. Cholesterol reduction in cardiovascular disease. Clinical benefits and possible mechanisms. N En J Med 1995;332:512-521.
16. Levy D, Salomon M, D'Agostino RB, Belanger AJ, Kannel WB. Prognostic implications of baseline electrocardiographic features and their serial changes in subjects with left ventricular hypertrophy. Circulation 1994;90:1786-1793.
17. Kannel WB, D'Agostino RB, Wilson PW, Belanger AJ, Gagnon DR. Diabetes, fibrinogen and risk of cardiovascular disease: The Framingham experience. Am Heart J 1990;120:672-676.
18. Kannel WB, Wolf PA, Castelli WP, D'Agostino RB. Fibrinogen and risk of cardiovascular disease. The Framingham Study. JAMA 1987;258:1183-1186.
19. Ernst E. Fibrinogen: The plot thickens. J Clin Epidemiol 1992;45:561-562.
20. DeFronzo RA, Feranerini E. Insulin resistance; a multifactorial syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia and atherosclerotic cardiovascular disease. Diabetes Care 1991;14:173-194.
21. Kannel WB, Wilson PWF. Risk factors that attenuate the female coronary disease advantage. Arch Intern Med 1995;155:57-61.
22. Cupples LA, Gagnon DR, Kannel WB. Long and short-term risk of sudden coronary death. Circulation 1992;85(Suppl 1):111-118.
23. Kannel WB, Plehn J, Cupples LA. Cardiac failure and sudden death in the Framingham Study. Am Heart J 1988;115:869-875.
24. Kannel WB, McGee DL, Schatzkin A. An epidemiological perspective of sudden death. 26-year follow-up in the Framingham Study Drugs 1984;28(Suppl 1):1-16.
25. Kannel WB. Epidemiological aspects of heart failure 1989;7:1-9.
26. Kannel WB, Ho K, Thom T. Changing epidemiological features of cardiac failure. Br Heart J 1994;(Suppl):S3-S9.
27. Ho KKL, Anderson KM, Kannel WB, Grossman W, Levy D. Survival after onset of congestive heart failure in Framingham Heart Study subjects. Circulation 1993;88:107-115.
28. Pfeffer MA, Braunwald E, Moyé LA, et al. for the SAVE investigators. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. N Eng J Med 1992;327:669-677.
29. Wong ND, Wilson PWF, Kannel WB. Serum cholesterol as a prognostic factor after myocardial infarction. The Framingham Study. Ann Intern Med 1991;115:687-693.
30. Genest J Jr, McNamara JR, Ordovas JM, et al. Lipoprotein cholesterol, apolipoprotein A-1 and B and lipoprotein (a) abnormalities in men with premature coronary artery disease. J Am Coll Cardiol 1992;19:792-802.
31. Kannel WB. Potency of vascular risk factors as the basis for antihypertensive therapy. Eur Heart J 1992;13(Suppl G):34-42.
32. Kannel WB, McGee DL, Diabetes and glucose tolerance as risk factors for cardiovascular disease: The Framingham Study. Diabetes Care 1979;2:120-126.
33. Kannel WB, Anderson K, Wilson PWF. White blood cell count and cardiovascular disease. JAMA 1992;267:1253-1256.
34. Ensrud K, Griman RH. The white blood cell count and risk of coronary heart disease. Am Heart J 1992;124:207-213.
35. Kannel WB. Epidemiology of cardiovascular disease in the elderly: An assessment of risk factors. In: Brest AN, Wilson JC, FA Davis, eds. Cardiovascular Clinics. Philadelphia: 1992:9-22.
36. Selhub J, Jacques PF, Wilson PWF, Rush D, Rosenberg IH. Vitamin status and intake as primary determinants of homocysteinemia in the elderly. JAMA 1993;270:2693-2698.
37. Stampfer MJ, Malinow MR, Willett WC, et al. A prospective study of plasma homocysteine and risk of myocardial infarction in US physicians. JAMA 1992;268:877-881.
38. Selhub J, Jacques PF, Bostom AG, et al. Association between plasma homocysteine and extracranial carotid stenosis. N Engl J Med 1995;332:286-291.
39. Rosengren A, Wilhelmsen L, Erikson E, Risberg B, Wedel H. Lipoproteins and coronary heart disease: A prospective case-control study in a general population sample of middle-aged men. Br Med J 1990;301:1248-1251.
40. Kang SS, Wong PWK, Norusis M. Homocysteinemia due to folate deficiency. Metabolism 1987;36:4358-462.
41. Smolin LA, Benevenga NJ. Accumulation of homocysteine in vitamin B6 deficiency. J Nutr 1982;112:1264-1272.
42. Brattstrom L, Israelsson B, Lindgarde F, Hultberg B. Higher total plasma homocysteine in vitamin B12 deficiency than in heterozygosity for homocysteinemia due to cystathionine B-synthase deficiency. Metabolism 1988;37:175-178.
43. Uterman G. The mysteries of lipoprotein (a). Science 1990; 246:904-910.
44. Austin MA, Breslow JL, Hennekens CH, Buring JE, Willett WC, Krauss RM. Low density lipoprotein subclass patterns and risk of myocardial infarction. JAMA 1988;260:1917-1921.
45. Janhiatnen M, Koskinen P, Euholm C, et al. Lipoprotein (a) and coronary heart disease risk: A nested case-control study of the Helsinki Heart Study participants. Atherosclerosis 1991;89:59-67.
46. Steinberg D. Workshop Participants. Antioxidants in the prevention of human atherosclerosis. Circulation 1992;85:2337-2344.